Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Research
Study finds HIV can evolve to resist lenacapavir—at a cost
After exposure to lenacapavir, HIV was able to shift the structure of its protein coating to avoid the drug’s effects.
Darren Incorvaia
Jan 7, 2026 2:00pm
Gilead garners lipid package for cancer asset in $300M pact
Jan 6, 2026 7:00am
AbbVie, Gilead gift themselves clinical-stage cancer drugs
Jan 2, 2026 10:35am
Gilead pays $35M to license pair of HSV assets from Assembly Bio
Dec 22, 2025 10:35am
Pfizer RNA leader runs to Replicate—Chutes & Ladders
Dec 19, 2025 8:30am
Arcus halts Gilead-partnered TIGIT trials as it reworks R&D
Dec 12, 2025 10:00am
